President Joe Biden’s administration is considering a reassessment of Medicare Part B premiums after the drugmaker behind a new Alzheimer’s drug cut its price. The administration announced in November 2021 that the monthly premium would rise by nearly $22 and attributed the rise in part to the potential use of Aduhelm, an Alzheimer’s drug from Biogen Inc. The uncertainty surrounding the drug triggered a need to increase contingency reserves, officials said. The following month, Biogen announced it was slashing the price of Aduhelm to $28,200. Michel Vounatsos, Biogen’s CEO, said in a statement at the time that company executives hoped the price drop would help the Centers for Medicare and Medicaid Services (CMS) decide to cover Aduhelm. On Monday, Health Secretary Xavier Becerra instructed CMS “to reassess the recommendation for the 2022 Medicare Part B premium, given the dramatic price change of the Alzheimer’s drug.” With the price decrease, “there is …